National Cancer Institute · company speakers →
Dr. Sharon will discuss efforts to learn more about off-target effects of immunotherapy, including efforts to collect clinical data and samples from national clinical trials, sponsored by the NCI and other academic organizations. Through efforts focused on translational science, the pathogenesis and eventual treatments for these irAEs may expand the reach of immunotherapy through better management of toxicity, as well as elucidate mechanisms behind similar cognate autoimmune syndromes that arise spontaneously. Immunotherapy is revolutionizing cancer care, primarily through the use of immune checkpoint inhibitors (ICIs) in an increasing number of histologies and settings. Unfortunately, ICIs and other immunotherapy agents have been associated with immune-related Adverse Events (irAEs), which are rare but serious sequelae of treatment with immuno-oncology therapeutics. These therapeutics include monoclonal antibody antagonists targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →